{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-088203","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.118219+00:00","generated_at":"2026-05-15T22:18:44.953866+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana Q4 net loss $58.8M; UP421 islet cells function at 1 year no immunosuppression; new $150M ATM filed","bullets":["UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.","Expect to file IND for SC451 (stem cell-derived islet therapy) and begin Phase 1 trial this year.","SG293 in vivo CAR T: NHP data show deep B-cell depletion; first-in-human data expected this year.","Q4 2025 net loss $58.8M ($0.21/shr); R&D $34.9M; cash $138.4M; runway into late 2026.","Entered new ATM agreement with TD Cowen for up to $150M; raised $133.7M gross from equity in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-088203","json":"https://secwatch.observer/filing/0001193125-26-088203.json","markdown":"https://secwatch.observer/filing/0001193125-26-088203.md","text":"https://secwatch.observer/filing/0001193125-26-088203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/0001193125-26-088203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/sana-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:18:44.953866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}